NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/06/2026
Back to search
Official data from USPTO
IKSUDA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
IKSUDA
ST13
US500000079240120Class
1, 5, 16, 42
Filing
79240120
Registration
5766418
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
08/06/2026
Trademark type
Word
Nice classes
1, 5, 16, 42
Filing date
05/17/2018
Registration date
06/04/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/08/2025
Last transaction
08/06/2026
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
MICHOS, JOHN E
Current location
Historical data usage
Holders and representatives
Holders
IKSUDA THERAPEUTICS LIMITED
Representatives
William S. Fultz Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 1Class 5Class 16Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; chemical preparations for scientific and industrial processesvinyl pyridine-based linkersvinyl pyridine derivativesdifluorosialic acid; enzymes for industrial use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs
Class 5
Pharmaceuticals for the treatment of cancer; pharmaceuticals and medical preparations for the treatment of inflammatory diseases; vaccines for the treatment of cancer; vaccines for the treatment of gene and cell therapy; vaccines for the treatment of inflammatory diseases; pharmaceutical and medical preparations for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical products for the prevention and treatment of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals for the treatment of inflammatory diseases; hormones and analogues for medical purposes; biopharmaceutical and pharmaceutical gene and cell therapy productstherapeutic pharmaceuticals for the treatment of cancertumorsinfectiousoncologicalautoimmuneimmune system diseases and disorders
Class 16
Paper; cardboard; printed matterpaper signsbooksmanualsbusiness cardsnewslettersinformational cardspostersbrochuresletterscertificates in the field of biotherapeutics; bookbinding material; photographs; stationery; printed instructionaleducationalteaching materials in the field of medicine; publicationsbookshand-outsworkbookspostersresearch articles in the fields of sciencemedicine and biotherapeutics; publications for the medical professionmagazinesnewslettersresearch articles in the field of medicine
Class 42
Scientific and technological servicesscientific researchdesignanalysis and testing in the field of biotherapeutics for treating cancer; medical and pharmaceutical research services; research and development of vaccines and medicines; industrial analysis and research servicessynthetic chemistrybioconjugationscientific analysis of antibody-drug conjugates and biotherapeutics; scientific research; pharmaceutical research; biological research; biotechnology testing servicessynthetic chemistryrecombinant protein productionbioconjugationtestinganalysisevaluation of antibody-drug conjugates and biotherapeutics to assure compliance with industry standards; medical research services in the field of cancer; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; conducting clinical trials for others; design of clinical trials for others in the field of vaccines and gene therapy; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; informationadvisory and consultancy services relating to the aforesaid
Publications
History of USPTO decisions and trademark events.
38 publications found
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
06/08/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
10/08/2025
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
10/08/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/06/2025
ES71
TEAS SECTION 71 RECEIVED
06/27/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/29/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/04/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/12/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/22/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/18/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/12/2019
FIMP
FINAL DISPOSITION PROCESSED
09/12/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/04/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
06/04/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/26/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/26/2019
PUBO
PUBLISHED FOR OPPOSITION
03/19/2019
GPNX
NOTIFICATION PROCESSED BY IB
03/16/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/27/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/27/2019
NPUB
NOTICE OF PUBLICATION
02/27/2019
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/13/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/11/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/07/2019
ALIE
ASSIGNED TO LIE
02/04/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/01/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/31/2019
RFNT
REFUSAL PROCESSED BY IB
10/13/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/24/2018
RFRR
REFUSAL PROCESSED BY MPU
09/24/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/18/2018
MAFR
APPLICATION FILING RECEIPT MAILED
09/18/2018
CNRT
NON-FINAL ACTION WRITTEN
09/17/2018
DOCK
ASSIGNED TO EXAMINER
09/13/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/13/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/06/2018
Continuous trademark protection
Get notified about every new filing that threatens IKSUDA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.